Federal Register Notice: FDA will hold a meeting of the Arthritis Advisory Committee 6/23-24, from 8 a.m. to 5 p.m. at the Holiday Inn, Bethesda, MD. On 6/23, the committee will discuss fibromyalgia, clinical trial design, including important disease endpoints in the study, and development of therapies and treatments. On 6/24, the committee will discuss the safety and efficacy of submission tracking number Immunex’ Enbrel (etanercept) for reducing signs and symptoms of active ankylosing spondylitis. Contact Johanna Clifford, (301) 827-7001. To view this notice, click here.
